GL1X · GenesisL1 explorer

MolNFT v1 · #122367 · protein

Anaplastic lymphoma kinase (ALK) catalytic domain complexed with novel inhibitor 3-sulfonylpyrazol-4-amino pyrimidine

5IMX · ALK tyrosine kinase receptor: “Anaplastic lymphoma kinase (ALK) catalytic domain complexed with novel inhibitor 3-sulfonylpyrazol-4-amino…”. X-ray diffraction, 1 ligand (CZ4), 1 pocket (best druggability 0.60). MolNFT v1 #122367 on…

PDB
5IMX
Type
protein
Length
266 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
ALK tyrosine kinase receptor
EC
2.7.10.1
UniProt
Q9UM73
Ligands
CZ4
Pockets
1 · best druggability 0.60

Structure

x-ray diffraction · 1 distinct chain · 39% helix, 14% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AALK tyrosine kinase receptor (EC 2.7.10.1)protein26639% helix, 14% strandQ9UM73

Ligands and binding sites

  • CZ4 · 5-chloro-N~2~-{5-methyl-4-(1-methylpiperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N~4~-{1-methyl-3-[(propan-2-yl)sulfonyl]-1H-pyrazol-4-yl}pyrimidine-2,4-diamine · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12680.600.7935CZ4

Compared structures

  • 5IMX · Anaplastic lymphoma kinase (ALK) catalytic domain complexed with novel inhibitor… · the same entry in another collection · chain A against A, TM-score 1.00
  • Q9UM73 · AlphaFold monomer V2.0 prediction for ALK tyrosine kinase receptor (Q9UM73) · a predicted model of the same protein · chain A against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.